Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

NCT05156970 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

81

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Head and Neck Squamous Cell Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Camrelizumab
DRUG: Cisplatin
DRUG: Docetaxel
DRUG: Apatinib Mesylate
DRUG: Carboplatin

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University